Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Neoplasms × pembrolizumab × Clear all

Phase

Phase 1 70 Phase 1/2 40 Phase 2 30 Phase 3 8 Phase NA 3 Phase EARLY_PHASE1 2 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Carcinoma, Non-Small-Cell Lung 2 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Pancreatic Neoplasms 1 Non-Small Cell Lung Cancer Metastatic 1 Neoplasms 1 Melanoma 1 Glioblastoma 1

Interventions

Dexamethasone 7 Oxycodone 6 Propofol 4 Epoetin Alfa 4 Zoledronic Acid 3 Sevoflurane 3 Palonosetron 3 Ondansetron 3 Naloxone 3 Everolimus 3 Cholecalciferol 3 Calcium Dobesilate 3 Bevacizumab 3 Aspirin 3 Aprepitant 3 peginterferon alfa-2a 2 edoxaban 2 apixaban 2 apatinib 2 Vitamin B 12 2 Vancomycin 2 Tobacco Use Cessation Devices 2 Tablets 2 Surgical Procedures, Operative 2 Sodium Chloride 2 Saline Solution 2 Rivaroxaban 2 Octreotide 2 Morphine 2 Metoclopramide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06031233 2025-05-21

MINUTE

Isala

Phase 4 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡